Science & Technology
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1U44NS127351-01A1
Award Ceiling
$361K
Award Floor
$361K
Close Date
Mar 31, 2024
Total Funding
$361K
Expected Awards
1
Posted Date
Apr 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1U44NS127351-01A1
Description
SBIR Phase Phase I award: "IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy." awarded to Shift Pharmaceuticals Holdings, Inc. in Columbia, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $360,937. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.